What Happened
Mosaic Intelligence Labs, a San Francisco-based medical technology company, emerged from stealth on November 10, 2026 with $47 million in seed funding. The round was backed by investors including 8VC, Fundomo, Lingotto Innovation, and Obvious Ventures. No lead investor was named.
The company is developing what it calls full-stack intelligent surgical machines: sensing-enabled instruments, spatial intelligence software, and a robotic interface designed to help physicians understand and safely navigate the human body from within.
Mosaic is starting with endovascular intervention — procedures in which physicians guide flexible wires and catheters through blood vessels to deliver treatment. The company's goal is to extend the reach and precision of surgical expertise, so that complex procedures inside the body can be performed more safely and by more physicians.
The founders are Dr. Ileana Pirozzi, who serves as CEO, and Dr. Alison "Ali" Kight Mackanic, the company's CTO. The two met during their doctoral studies at Stanford University.
What the Company Does
Mosaic Intelligence Labs is building systems that give surgical instruments a sense of their surroundings. The core idea is to instrument the point where a surgical tool meets anatomy — to collect information about the environment as the tool moves through the body — and then use that data to build a continuously updated, three-dimensional view of the blood vessels and the instruments inside them.
That view matters because endovascular surgery is, in a sense, surgery performed blind. A physician threads a wire or catheter through the body's vascular network, navigating by X-ray images that are flat, intermittent, and expose both patient and physician to radiation. The company compares the scale of the intervention to other forms of surgery: open surgery uses a 20–30 cm incision, keyhole surgery uses 1–2 cm ports, and endovascular surgery needs only a 2 mm needle puncture. The smaller the entry point, the less trauma to the patient — but the harder it is for the physician to know exactly where the instrument is.
Mosaic's system is designed to change that. Sensing-enabled instruments feed data into computational systems that reconstruct the vascular environment in three dimensions, showing physicians where their tools are in real time. A robotic interface will let physicians control surgical tools through the system. And because the system records data from every procedure, it can learn from physician actions over time — improving navigation and, eventually, expanding the range of treatments that can be delivered through blood vessels.
Why It Matters
Endovascular procedures are one of the largest and fastest-growing areas of medicine. Stents, clot removal, aneurysm repair, and many cardiac procedures are now performed through blood vessels rather than open surgery, because patients recover faster and face fewer complications. But the procedures are technically demanding, and the supply of physicians skilled enough to perform them is limited. A system that makes these procedures easier, safer, and more consistent could expand access to treatment significantly.
The $47 million seed round is large by the standards of medical technology, where seed rounds are often far smaller. It reflects two things: the scale of the engineering challenge — Mosaic is building hardware, sensing, software, and robotics together, which is expensive — and investor confidence in the founding team. Both founders hold doctorates from Stanford, and the company has attracted backing from 8VC, a firm with a long history in healthcare and defence technology, alongside Obvious Ventures and others.
Investors and observers should keep one important caveat in mind. Mosaic's capabilities are development goals, not demonstrated results. The company's announcement supplies no patient-outcome findings or clinical-performance data, and its technology has not been shown to have received regulatory authorisation for clinical use. The road from a well-funded stealth launch to a product that physicians actually use runs through years of engineering, clinical validation, and regulatory review.
What This Means for Founders and Investors
For founders, Mosaic shows that deep-tech healthcare startups can raise large seed rounds when the team, the problem, and the market align. A founding team with Stanford doctorates, a problem rooted in a real clinical need, and a platform vision rather than a single device is the kind of combination that attracts top firms. Founders in medtech should note, however, that the bar is high: the announcement was accompanied by a full technical vision, a named clinical focus, and a team already hiring across multiple disciplines.
For investors, the round is a bet on the convergence of AI, sensing, and robotics in medicine. Surgical robotics has historically rewarded patient capital — Intuitive Surgical took years to reach scale — and Mosaic is likely to follow a similar path. The near-term milestones to watch are engineering hires, prototype demonstrations, and the first signs of clinical validation.
Angeled.com connects founders with investors.
Unite.AI
Tech Funding News
Citybiz
Pulse2
The AI Insider
Read Next
General Translation Raises $27 Million Series A Led by a16z to Build Agent-First Localization Infrastructure
LangChain Raises $300 Million Led by CapitalG at a $3 Billion Valuation to Build the Agent Stack
Mount Thor Raises $45 Million to Run Cloud Fleets of Macs for AI Agents
OpenAI Reportedly Raises $15 Billion at a $1.25 Trillion Valuation
Q-CTRL Raises $290 Million Series C Led by Salesforce Ventures, Reaching Unicorn Status
SE3 Raises $30 Million Series A Led by Accel



